TheraBionic Inc., is an innovative medical device company, and maker of the TheraBionic P1 medical device. TheraBionic Inc’s patented, tumor-specific radiofrequencies have shown to be effective in tumor shrinkage, blocking new cancer cell growth, and increased overall survival rates.
The TheraBionic P1 device is FDA approved for treatment of advanced hepatocellular carcinoma (HCC), the most common form of liver cancer in adult patients for whom first and second line therapies have failed.
How it works
The TheraBionic P1 is a portable device that emits low-level, tumor-specific radiofrequency electromagnetic fields throughout the body to target tumor-specific cancer cells. Treatment is administered at home via a spoon shaped antenna which is placed in the patient’s mouth for one hour, three times daily.
In multiple studies conducted over more than two decades, patients undergoing treatment using the TheraBionic P1 device, did not experience the debilitating side effects associated with other cancer-fighting therapies including loss of appetite, diarrhea, and irritation of the palms and soles.
The future of systemic, targeted treatment of cancer
The TheraBionic P1 device is currently being studied as first and second line treatment of HCC (meaning the TheraBionic P1 device with another treatment agent), and as first line treatment of stage 4 pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
It is FDA approved for treatment of hepatocellular carcinoma in patients 18 years and older for whom first and second line therapies have failed. The device will be available for general market use by the first quarter of 2024.